WR Wealth Planners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

WR Wealth Planners’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2	Closed	-$8	–	1001
2023 Q1	$8	Hold	2	–	–	﹤0.01%	931
2022 Q4	$12	Hold	2	–	–	﹤0.01%	499
2022 Q3	$12	Hold	2	–	–	﹤0.01%	521
2022 Q2	$12	Hold	2	–	–	﹤0.01%	524
2022 Q1	$9	Buy	+2	New	+$6	﹤0.01%	517

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

WR Wealth Planners's CTIC Position: Q2 2023 in Review

WR Wealth Planners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 2 shares — an estimated $8 sold.

WR Wealth Planners first reported a position in CTIC in Q1 2022 and held it in 5 quarters. The position peaked at $12 in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

WR Wealth Planners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
WR Wealth Planners sold 2 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $8.
WR Wealth Planners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 5 quarters.
WR Wealth Planners's CTI BioPharma Corp. (DE) Common Stock position peaked at $12 in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on WR Wealth Planners's 13F filing for Q2 2023, filed 1 Aug 2024.